Ceftolozane/tazobactam: A new option in the treatment of complicated gram-negative infections

P and T

Volumn 39, Issue 12, 2014, Pages 825-832

  Sorbera, Maria ^a   Chung, Elizabeth ^b   Ho, Christopher W ^b,c   Marzella, Nino ^b,c  

^a BROOKLYN HOSPITAL CENTER   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c LONG ISLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BETA LACTAMASE SHV 1; BETA LACTAMASE TEM 1; BETA LACTAMASE TEM 2; CEFTOLOZANE; CEPHALOSPORIN; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; PENICILLIN BINDING PROTEIN; TAZOBACTAM; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; CHEMICAL STRUCTURE; CLINICAL PHARMACOLOGY; CONSTIPATION; CREATININE CLEARANCE; DIARRHEA; DRUG ACTIVITY; DRUG HALF LIFE; ESCHERICHIA COLI; FEVER; GRAM NEGATIVE INFECTION; HEADACHE; HUMAN; HYPERTENSION; INJECTION SITE PHLEBITIS; INSOMNIA; KLEBSIELLA PNEUMONIAE; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; MODERATE RENAL IMPAIRMENT; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING;

EID: 84920505763     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. April 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed June 1, 2014.
2. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009;49(8):1175–1184.
3. Alliance for the Prudent Use of Antibiotics. The cost of antibiotic resistance to U.S. families and the health care system. Available at: http://www.tufts.edu/med/apua/consumers/personal_home_5_1451036133.pdf. Accessed June 1, 2014.
4. Rice LB. Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol 2010;31(suppl 1):S7–S10.
5. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50(2):133–164.
6. Campfeld B, Chen K, Kolls JK. Vaccine approaches for multidrug resistant Gram negative infections. Curr Opin Immunol 2014;28:84–89.
7. Moyá B, Zamorano L, Juan C, et al. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Che-mother 2010;54(9):3933–3937.
8. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 2011;55(5):2390–2394.
9. Lucasti C, Hershberger E, Miller B, et al. A multicenter, double-blind, randomized, phase 2 study to assess the safety and efficacy of ceftolozane/tazobactam (TOL/ TAZ) plus metronidazole (MTZ) compared with meropenem (MER) in adult patients with complicated intra-abdominal infections (cIAI). [Abstract K-1709] Poster presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2013; Denver, Colorado, September 10–13, 2013.
10. Cubist Pharmaceuticals. Cubist presents detailed results from positive phase 3 trials of ceftolozane/tazobactam at 2014 European Congress of Clinical Microbiology and Infectious Diseases (ECC-MID). Available at: http://www.cubist.com/media/news-releases/cubist-pres-ents-detailed-results-from-positive-pha. Accessed June 1, 2014.
11. Hong MC, Hsu DI, Bounthavong M. Ceftolozane/tazobactam: a novel anti pseudomonal cephalosporin and β-lactamase-inhibitor combination. Infect Drug Resist 2013;6:215–223.
12. Van Hoek AH, Mevius D, Guerra B, et al. Acquired antibiotic resistance genes: an overview. Front Microbiol 2011;2:203.
13. Takeda S, Nakai T, Wakai Y, et al. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2007;51(3):826–830.
14. Moyá B, Beceiro A, Cabotg, et al. Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profles, and binding affinities. Antimicrob Agents Chemother 2012;56(9):4771–4778.
15. Miller B, Hershberger E, Benziger D, et al. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother 2012;6(6):3086–3091.
16. Miller B, Chandorkar G, Umeh O, et al. Safety and PK of IV ceftolozane/tazobactam 3 g every eight hours and cumulative fraction of response in plasma and epithelial lining fluid in a simulated VAP population. [Abstract A-641] Presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 9–12, 2012.
17. Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs 2014;74(1):31–51.
18. Cubist Pharmaceuticals. Ceftolozane/ tazobactam—overview.
19. Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. Clin Microbiol Rev 2010;23(1):160–201.
20. Bush K, Macalintal C, Rasmussen BA, et al. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother 1993;37(4):851–858.
21. Clinicaltrials.gov. Safety and efficacy study to compare IV CXA 101/tazobactam and metronidazole with meropenem in complicated intraabdominal infections. NCT01147640. Available at: http://clinicaltrials.gov/ct2/show/NCT01147640?term=NCT01147640&rank=1. Accessed June 1, 2014.
22. Cubist Pharmaceuticals. Cubist announces positive top-line results from phase 3 trial of investigational antibiotic ceftolozane/tazobactam in complicated urinary tract infections. November 25, 2013. Available at: http://www.cubist.com/media/news-releases/cubist-announces-positive-top-line-results-fro-(1). Accessed June 1, 2014.
23. Clinicaltrials.gov. Study comparing the safety and efficacy of intravenous CXA-201 and intravenous levofloxacin in complicated urinary tract infection, including pyelonephritis. NCT01345929. Available at: http://clinicaltrials.gov/ct2/show/NCT01345929?term=NCT01345929&rank=1. Accessed June 1, 2014.
24. Cubist Pharmaceuticals. Cubist announces positive top-line results from phase 3 trial of ceftolozane/ tazobactam in intra-abdominal infections. December 16, 2013. Available at: http://investors.cubist.com/Mobile/fle.aspx?IID=4093793&FID=21288226. Accessed October 31, 2014.
25. Clinicaltrials.gov. Safety and efficacy of intravenous CXA-201 and intravenous meropenem in complicated intraabdominal infections. NCT01445665. Available at: http://clinicaltrials.gov/ct2/show/NCT01445665?term=NCT01445665&rank=1. Accessed June 1, 2014.
26. Clinicaltrials.gov. Study comparing the safety and efficacy of intravenous CXA-201 and intravenous meropenem in complicated intraabdominal infections. NCT01445678. Available at: http://clinicaltrials.gov/ct2/show/NCT01445678?term=NCT01445678&rank=1. Accessed June 1, 2014.
27. Clinicaltrials.gov. Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia (ASPECT-NP). NCT02070757. Available at: http://clinicaltrials.gov/ct2/show/study/NCT02070757?term=Ceftolozane%2FTazobactam&rank=1. Accessed June 1, 2014.
28. Cubist Pharmaceuticals. Cubist presents detailed results from positive phase 3 trials of ceftolozane/tazobactam at 2014 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). May 9, 2014. Available at: http://investors.cubist.com/Mobile/file.aspx?IID=4093793&FID=23570682. Accessed October 31, 2014.
29. Wooley M, Miller B, Krishma G, et al. Impact of renal function on the pharmacokinetics and safety of ceftolozane/ tazobactam. Antimicrob Agents Chemother 2014;58(4):2249–2255.
30. Rocephin [package insert]. South San Francisco, California: Genentech USA, Inc.; 2013.
31. Zosyn [package insert]. Philadelphia, Pennsylvania: Wyeth Pharmaceuticals Inc.; 2013.
32. Merk Manual [website]. β-lactams. 2013. Available at: http://www.merck-manuals.com/professional/infectious_diseases/bacteria_and_antibacterial_drugs/%CE%B2-lactams.html. Accessed April 2, 2014.
33. Boucher HW, Talbot GH, Benjamin DK, et al. 10 × 20 progress—development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013;56(12):1685–1694.
34. Cubist Pharmaceuticals. Cubist announces acceptance of ceftolozane/tazobactam new drug application with priority review. June 19, 2014. Available at: http://www.cub-ist.com/media/news-releases/cubist-announces-acceptance-of-ceftolozane-tazobac. Accessed November 4, 2014.